Zai Lab (9688.HK) Stock Price

Zai Lab Price

HKEX·CLOSED
2.28
​
Market closed

Over the last 7 years Zai Lab grew revenue by 221.6% annually, reaching 460.84 M USD. For Zai Lab, the net margin of -38.1% is up versus -479.8% a few years ago. The consensus 12-month price target for Zai Lab is 3.18 USD, about 39.6% above where the stock trades today. Of 14 analysts, 11 rate the stock a buy — an overall Buy consensus.

Zai Lab stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab business model & stock analysis

Zai Lab Ltd. focuses on discovering, developing, and commercializing proprietary therapeutics for unmet medical needs in China, particularly in oncology, autoimmune, and infectious diseases. The company's pipeline includes drug candidates such as Niraparib (ZL-2306), ZL-2103, and ZL-1101, which are in various stages from discovery to late-stage clinical programs. Its products target large patient segments requiring innovative treatments within the Chinese healthcare market. The firm's revenue comes from the commercialization of its proprietary drug candidates, which are developed through internal research and strategic partnerships. Zai Lab Ltd. serves the Chinese biopharmaceutical market, targeting healthcare providers, hospitals, and patients seeking advanced therapies for conditions like cancer and autoimmune disorders. The company leverages its pipeline to generate sales through pharmaceutical distribution channels in China.

Frequently asked questions about Zai Lab

Analysts currently set an average price target of 3.75 USD for the Zai Lab stock (median: 3.18 USD), implying +69.5 % versus the latest price. The consensus is based on 14 analyst ratings.

14 analysts currently rate the Zai Lab stock: 11 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Zai Lab to generate revenue of 439.13 M USD and earnings per share of -0.02 USD.

Converted at the current exchange rate, the Zai Lab share trades at 2.07 EUR (2.28 USD).

The Zai Lab share (9688.HK) is listed on 1 stock exchanges, including: Hongkong (HKEX) (9688.HK).

The expected revenue of Zai Lab is 439.13 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zai Lab is -23.73 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zai Lab is currently -106.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zai Lab stock.

The price-to-sales ratio (P/S) of Zai Lab is currently 5.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zai Lab stock.

The Eulerpool Quality Score for Zai Lab is 3/10.

The ISIN of Zai Lab is KYG9887T1168. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Zai Lab is A2DX7H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Zai Lab is 9688.HK. The ticker symbol is used to trade Zai Lab shares on the stock exchange.

Fair ValueTerminal
2.05 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
385,960.39 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Sep 28, 2020
ISIN
KYG9887T1168
Cusip
G9887T108
Sedol
BMGWNM6
Market capitalization
2.25 B USDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-106.20
P/Ee 2027
-36.64
P/Ee 2028
-18.71
P/Ee 2029
33.06
P/Ee 2030
13.00
P/S
P/Se
5.74
EV/EBIT
—
P/B Ratio
3.15
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-18.71 %
Last updated Nov 20, 2026, 3:33 AM

All fundamentals and in-depth analysis of Zai Lab

Our stock analysis for Zai Lab stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zai Lab. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.